Apogee Therapeutics, Inc. (APGE)
135.08
0.00 (0.00%)
USD |
NASDAQ |
Sep 01, 16:00
135.02
-0.06
(-0.04%)
After-Hours: 20:00
Apogee Therapeutics Cash from Investing (Quarterly) : -381.86M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -381.86M |
| March 31, 2026 | -35.35M |
| December 31, 2025 | -288.63M |
| September 30, 2025 | 17.94M |
| June 30, 2025 | 78.12M |
| March 31, 2025 | 12.98M |
| December 31, 2024 | 46.37M |
| September 30, 2024 | -146.38M |
| June 30, 2024 | -148.71M |
| Date | Value |
|---|---|
| March 31, 2024 | -51.74M |
| December 31, 2023 | -273.91M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Cogent Biosciences, Inc. | 14.28M |
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Intellia Therapeutics, Inc. | -141.57M |
| Revolution Medicines, Inc. | -1.659B |
| Erasca, Inc. | 19.49M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -71.38M |
| Cash from Financing (Quarterly) | 107.02M |
| Free Cash Flow | -243.96M |
| Free Cash Flow Per Share (Quarterly) | -0.9461 |
| Free Cash Flow to Equity (Quarterly) | -169.40M |
| Free Cash Flow to Firm (Quarterly) | -69.80M |
| Free Cash Flow Yield | -2.66% |